Jose Gamez, MD
Psychiatry · Hialeah, FLNPI 1134210271
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $434,020 of the $557,144 with a category attached, or 77.9%. 27 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 36.7% of the total. Reporting peaked in 2023 at $162,794 and has fallen 53.4% since, to $75,935 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,036 payments — averaging $537.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$205K
- Acadia Pharmaceuticals Inc$161K
- Otsuka America Pharmaceutical, Inc.$76K
- AbbVie$43K
- Teva Pharmaceuticals USA, Inc.$37K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
- plus $20K from 21 others
Across 1,445 payments — averaging $9839.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$5.8M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.7M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.2M
- Eisai Inc.$890K
- Hoffmann-la Roche Limited$769K
- Janssen Research & Development, LLC$609K
- plus $3.2M from 27 others
What the payments were for
- Consulting fees$55,60610%
- Speaking & faculty fees$434,02078%
- Travel & lodging$37,4687%
- Food & beverage$30,0505%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 269 | $204,736 |
| Acadia Pharmaceuticals Inc | 224 | $161,117 |
| Otsuka America Pharmaceutical, Inc. | 131 | $76,093 |
| AbbVie(2 entities) | 97 | $43,325 |
| Teva Pharmaceuticals USA, Inc. | 94 | $36,678 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 61 | $15,676 |
| E.r. Squibb & Sons, L.L.C. | 37 | $12,019 |
| Livanova USA, Inc. | 12 | $1,496 |
| Alkermes, Inc. | 21 | $1,076 |
| Bristol Myers Squibb | 3 | $772 |
| Bausch Health US, LLC | 25 | $584 |
| Johnson & Johnson | 5 | $546 |
| Sunovion Pharmaceuticals Inc. | 6 | $415 |
| Avanir Pharmaceuticals, Inc. | 5 | $406 |
| Eisai Inc. | 3 | $350 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $292 |
| Axsome Therapeutics, Inc. | 4 | $254 |
| Jazz Pharmaceuticals Inc. | 2 | $244 |
| Lundbeck LLC | 8 | $212 |
| Corium, LLC | 4 | $178 |
| Almatica Pharma LLC | 6 | $155 |
| Vanda Pharmaceuticals Inc. | 6 | $134 |
| Amgen | 1 | $115 |
| Idorsia Pharmaceuticals US Inc | 2 | $109 |
| Alpha Cognition USA, Inc. | 3 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Merck | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$198,785
- NUPLAZID$157,130
- REXULTI$73,933
- VRAYLAR$41,694
- UZEDY$33,625
- CAPLYTA$14,324
- ARISTADA$1,787
- LYBALVI$1,444
- VNS Therapy$1,126
- Ozanimod$772
- Austedo XR$715
- AUSTEDO$611
- COBENFY$594
- ARISTADA INITIO$447
- NUEDEXTA$367
- LATUDA$359
- SPRAVATO$341
- ABILIFY MAINTENA$240
- Dayvigo$225
- Auvelity$218
How this compares
$557,144 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 142 | $1,137,169 |
| NuplazidPimavanserin Tartrate | 97 | $417,655 |
| RexultiBrexpiprazole | 80 | $117,988 |
| VraylarCariprazine Hcl | 52 | $96,554 |
| CaplytaLumateperone Tosylate | 40 | $68,743 |
| AplenzinBupropion Hbr | 22 | $59,814 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $41,830 |
| Chlorpromazine Hcl | 80 | $34,427 |
| Wellbutrin XlBupropion Hcl | 12 | $31,605 |
| NamzaricMemantine Hcl/Donepezil Hcl | 39 | $24,032 |
| Aripiprazole | 105 | $13,992 |
| Clonazepam | 1,083 | $9,968 |
| Temazepam | 664 | $9,303 |
| Alprazolam | 681 | $9,005 |
| Quetiapine Fumarate | 453 | $8,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $204,736 | $1,137,169142 claims |
| Acadia Pharmaceuticals IncNuplazid | $161,117 | $417,65597 claims |
| AbbVieVraylar, Namzaric | $43,325 | $120,58691 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $76,093 | $117,98880 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $15,676 | $68,74340 claims |
| Bausch Health US, LLCAplenzin | $584 | $59,81422 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $406 | $41,83039 claims |
| Almatica Pharma LLCSertraline Hcl | $155 | $952217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Hialeah
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.